en · de · es · fr · pt
cjc-1295-notes.peptides4962.com › Blog › Background And Receptor Mechanism — What the Evidence Shows

Background And Receptor Mechanism — What the Evidence Shows

By Editorial Desk · published 2025-08-21 · last reviewed 2025-09-12 · Blog

If you have been reading about MOD GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Receptor Mechanism

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

Handling Storage And Analytical Methods

Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.

Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight, DAC formAbout 3647 DaVaries with salt form
Molecular weight, non-DAC formAbout 3358 DaMOD GRF(1-29)
Solubility classWater solubleAlso dissolves in polar solvents
Reported half-life, DAC formAbout five to eight daysValues from human studies
Common synonymsCJC-1295; MOD GRF(1-29)Name depends on variant

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Related pages on this site

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Supporting material

Cyproheptadine is a potent antihistamine or inverse agonist of the histamine H1 receptor. It also has anticholinergic, antiserotonergic, antidopaminergic, and local anesthetic activities. In one study, cyproheptadine had about the same affinity for the serotonin 5-HT2A and 5-HT2B receptors as for the histamine H1 receptor, about 8-fold selectivity for the histamine H1 receptor over the serotonin 5-HT2C receptor, about 2- to 8-fold selectivity for the H1 receptor over the muscarinic acetylcholine receptors, and about 4- to 52-fold selectivity for the histamine H1 receptor over the dopamine receptors. The drug shows lower affinity for α-adrenergic receptors and little to no affinity for the monoamine transporters. Of the serotonin receptors, it is an especially potent antagonist of the 5-HT2 receptors. This is thought to underlie its effectiveness in the treatment of serotonin syndrome. However, it is possible that blockade of 5-HT1 receptors may also contribute to its effectiveness in serotonin syndrome. Cyproheptadine has been reported to block 85% of 5-HT2 receptors in the human brain at a dose of 4 mg three times per day (12 mg/day total) and to block 95% of 5-HT2 receptors in the human brain at a dose of 6 mg three times per day (18 mg/day total) as measured with positron emission tomography (PET). The most widely used dose of cyproheptadine for serotonin syndrome has been said to be 4 mg, though doses of up to 16 mg have been used.

Cadmium at The Periodic Table of Videos (University of Nottingham) ATSDR Case Studies in Environmental Medicine: Cadmium Toxicity Archived 18 December 2020 at the Wayback Machine U.S. Department of Health and Human Services National Institute for Occupational Safety and Health – Cadmium Page NLM Hazardous Substances Databank – Cadmium, Elemental

== Collection of tissues == Histopathological examination of tissues starts with surgery, biopsy, or autopsy. The tissue is removed from the body or plant, and then, often following expert dissection in the fresh state, placed in a fixative which stabilizes the tissues to prevent decay. The most common fixative is 10% neutral buffered formalin (corresponding to 3.7% w/v formaldehyde in neutral buffered water, such as phosphate buffered saline).

Sources: en.wikipedia.org

Notes from published material

Due to competition, the early 1980s recession, the early 1990s recession, and lost focus, the company's growth stalled in the 1980s and early 1990s. D’Arbeloff, the chairman of the company, died of cancer and the COO and CTO died in a helicopter crash while commuting between facilities. The anticipated synergies never materialized. In 1994, an investor group led by management purchased the company for $360 million. That year, the company introduced Symmetry HPLC columns. It had a renewed focus for growth under CEO Douglas A. Berthiaume. Pharmaceutical spending also increased after the failure of the Clinton health care plan of 1993. In November 1995, the company once again became a public company via an initial public offering. In 1996, in addition to acquiring TA Instruments, it introduced the Alliance HPLC system. The following year, Waters acquired Micromass for $176 million, entering the mass spectrometry market. In 2004, the company introduced the Acquity UPLC system, which brought greater speed, resolution, and sensitivity to chromatographic separations and was considered a breakthrough technology. In 2006, Waters acquired Vicam, provider of bio-separation and rapid detection products for improving food safety and quality. In January 2020, it acquired Andrew Alliance, a producer of software and robotics for laboratory automation, for $77.4 million. In September, Udit Batra was named President and Chief Executive Officer of the company. In May 2023, Waters acquired Wyatt Technology for $1.36 billion in cash.

=== Molten carbonate fuel cells === Lithium titanate is used as a cathode in layer one of a double layer cathode for molten carbonate fuel cells. These fuel cells have two material layers, layer 1 and layer 2, which allow for the production of high power molten carbonate fuel cells that work more efficiently.

In medieval Germany, a metallic yellow mineral was found in the Ore Mountains that resembled copper ore. But when miners were unable to get any copper from it, they blamed a mischievous sprite of German mythology, Nickel (similar to Old Nick), for besetting the copper. They called this ore Kupfernickel from German Kupfer 'copper'. This ore is now known as the mineral nickeline (formerly niccolite), a nickel arsenide. In 1751, Baron Axel Fredrik Cronstedt tried to extract copper from kupfernickel at a cobalt mine in the village of Los, Sweden, and instead produced a white metal that he named nickel after the spirit that had given its name to the mineral. In modern German, Kupfernickel or Kupfer-Nickel designates the alloy cupronickel. Originally, the only source for nickel was the rare Kupfernickel. Beginning in 1824, nickel was obtained as a byproduct of cobalt blue production. The first large-scale smelting of nickel began in Norway in 1848 from nickel-rich pyrrhotite. The introduction of nickel in steel production in 1889 increased the demand for nickel; the nickel deposits of New Caledonia, discovered in 1865, provided most of the world's supply between 1875 and 1915. The discovery of the large deposits in the Sudbury Basin in Canada in 1883, in Norilsk-Talnakh in Russia in 1920, and in the Merensky Reef in South Africa in 1924 made large-scale nickel production possible.

Sources: en.wikipedia.org

Background from the literature

"Victims as Defenders: African Troops in the Rhodesian Defence System 1890–1980". Small Wars & Insurgencies. 2 (2): 240–275. doi:10.1080/09592319108422981. Molomo, Mpho G. (2009). "The Link between Sustainable Development and Security in Botswana". In Cawthra, Gavin (ed.). African Security Governance: Emerging Issues. Tokyo: United Nations University Press. pp. 131–156. ISBN 9789280811773. Melson, C. D. (2005). "Top Secret War: Rhodesian Special Operations". Small Wars and Insurgencies. 16 (1): 57–82. doi:10.1080/0959231042000322567. S2CID 145455177. Moorcraft, Paul L.; McLaughlin, Peter (1982). Chimurenga! The War in Rhodesia, 1965-1980. A Military history. Marshalltown, South Africa: Sygma/Collins. ISBN 0620062142. Moorcraft, P. L.; McLaughlin, P. (2010). The Rhodesian War: A Military History. Stackpole Books. ISBN 9780811707251. Morse, Stephen A. (2006). "Historical Perspectives of Microbial Bioterrorism". In Anderson, Burt; Friedman, Herman; Bendinelli, Mauro (eds.). Microorganisms and Bioterrorism. New York City: Springer. pp. 15–30. ISBN 9780387281568. O'Brien, Kevin (September 2001). "Counter-Intelligence for counter-revolutionary warfare: The South African police security branch 1979–1990". Intelligence and National Security. 16 (3): 27–59. doi:10.1080/02684520412331306200. S2CID 153561623. Palmer, Robin (October 1983). "Review: From Zimbabwe to Azania? A Review Article". African Affairs. 82 (329): 574–578. doi:10.1093/oxfordjournals.afraf.a097565. JSTOR 721219. Prokosh, Eric, ed. (1994). "Disappearances" and Political Killings: Human Rights Crisis of the 1990s.

==== Convergent evolution ==== Color change is widespread in ectotherms including anoles, frogs, mollusks, many fish, insects, and spiders. The mechanism behind this color change can be either morphological or physiological. Morphological change is the result of a change in the density of pigment containing cells and tends to change over longer periods of time. Physiological change, the kind observed in cephalopod lineages, is typically the result of the movement of pigment within the chromatophore, changing where different pigments are localized within the cell. This physiological change typically occurs on much shorter timescales compared to morphological change. Cephalopods have a rare form of physiological color change which utilizes neural control of muscles to change the morphology of their chromatophores. This neural control of chromatophores has evolved convergently in both cephalopods and teleosts fishes.

Veneer is obtained either by "peeling" the trunk of a tree or by slicing large rectangular blocks of wood known as flitches. The appearance of the grain and figure in wood comes from slicing through the growth rings of a tree and depends upon the angle at which the wood is sliced. There are three main types of veneer-making equipment used commercially:

=== Reconstructed set point === In healthy persons, the intra-individual variation of TSH and thyroid hormones is considerably smaller than the inter-individual variation. This results from a personal set point of thyroid homeostasis. In hypothyroidism, it is impossible to directly access the set point, but it can be reconstructed with methods of systems theory. A computerised algorithm, called Thyroid-SPOT, which is based on this mathematical theory, has been implemented in software applications. In patients undergoing thyroidectomy it could be demonstrated that this algorithm can be used to reconstruct the personal set point with sufficient precision.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

How do the DAC and non-DAC forms differ?

The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.

What receptor does it act on?

It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.

How should the dry powder be stored?

Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.

Network